anti-CGRP monoclonal antibodies
PreclinicalSmall molecule
anti-CGRP monoclonal antibodies is one of 38 small molecule programs targeting Migraine. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
105 competitors in Migraine
#DrugCompanyPhaseTrials
1Zonegran
AAzurity Pharmaceuticals
Phase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Magnesium
SSpherium Biomed
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
BAT7104
TevaPhase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
Adempas
BayerPreclinical
Cervidil
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIRCCS San Raffaele Roma